High-Throughput Sequencing of BACHD Mice Reveals Upregulation of Neuroprotective miRNAs at the Pre-Symptomatic Stage of Huntington's Disease

被引:7
|
作者
Olmo, Isabella G. [1 ]
Olmo, Roenick P. [1 ,2 ]
Goncalves, Andre N. A. [3 ]
Pires, Rita G. W. [4 ]
Marques, Joao T. [1 ,2 ]
Ribeiro, Fabiola M. [1 ]
机构
[1] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Biochem & Immunol, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Strasbourg, Inst Biol Mol & Cellulaire, INSERM, CNRS,UPR9022,U1257, Strasbourg, France
[3] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil
[4] Univ Fed Espirito Santo, Ctr Hlth Sci, Dept Physiol Sci, Vitoria, Brazil
来源
ASN NEURO | 2021年 / 13卷
关键词
BACHD; Huntington's disease; microRNA; miR-146b-5p; miR-449c-5p; pre-symptomatic stage; MOTILE CILIOGENESIS; MUTANT HUNTINGTIN; MICRORNAS; PATHWAY; MOUSE; PHOSPHORYLATION; ABNORMALITIES; DYSFUNCTION; BIOMARKERS; REPEAT;
D O I
10.1177/17590914211009857
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a genetic disorder marked by transcriptional alterations that result in neuronal impairment and death. MicroRNAs (miRNAs) are non-coding RNAs involved in post-transcriptional regulation and fine-tuning of gene expression. Several studies identified altered miRNA expression in HD and other neurodegenerative diseases, however their roles in early stages of HD remain elusive. Here, we deep-sequenced miRNAs from the striatum of the HD mouse model, BACHD, at the age of 2 and 8months, representing the pre-symptomatic and symptomatic stages of the disease. Our results show that 44 and 26 miRNAs were differentially expressed in 2- and 8-month-old BACHD mice, respectively, as compared to wild-type controls. Over-representation analysis suggested that miRNAs up-regulated in 2-month-old mice control the expression of genes crucial for PI3K-Akt and mTOR cell signaling pathways. Conversely, miRNAs regulating genes involved in neuronal disorders were down-regulated in 2-month-old BACHD mice. Interestingly, primary striatal neurons treated with anti-miRs targeting two up-regulated miRNAs, miR-449c-5p and miR-146b-5p, showed higher levels of cell death. Therefore, our results suggest that the miRNAs altered in 2-month-old BACHD mice regulate genes involved in the promotion of cell survival. Notably, over-representation suggested that targets of differentially expressed miRNAs at the age of 8months were not significantly enriched for the same pathways. Together, our data shed light on the role of miRNAs in the initial stages of HD, suggesting a neuroprotective role as an attempt to maintain or reestablish cellular homeostasis.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Tractography study of individuals with mutation for Huntington's disease in symptomatic and pre-symptomatic phases
    Saba, R. A.
    Yared, J.
    Doring, T.
    Borges, V.
    Barcelos, L. B.
    Ferraz, H. B.
    MOVEMENT DISORDERS, 2016, 31 : S356 - S356
  • [12] PAIN STIMULI PROCESSING IN PRE-SYMPTOMATIC AND EARLY HUNTINGTON'S DISEASE
    Franco, G.
    Serpino, C.
    Sciruicchio, V.
    Cormio, C.
    Ricci, K.
    deTommaso, M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A63 - A63
  • [13] A systematic linguistic profile of spontaneous narrative speech in pre-symptomatic and early stage Huntington's disease
    Hinzen, Wolfram
    Rossello, Joana
    Morey, Cati
    Camara, Estela
    Garcia-Gorro, Clara
    Salvador, Raymond
    de Diego-Balaguer, Ruth
    CORTEX, 2018, 100 : 71 - 83
  • [14] Identification of psychoeducation needs and an intervention response for pre-symptomatic Huntington's disease
    Gluyas, Cathy
    Mottram, Lisa
    Gibb, Rosanne
    Stout, Julie
    JOURNAL OF COMMUNITY GENETICS, 2023, 14 (02) : 175 - 183
  • [15] Trajectory control and motor learning in pre-symptomatic Huntington's disease (pHD)
    Ghilardi, F.
    Feigin, A.
    Moisello, C.
    Battaglia, F.
    Di Rocco, A.
    Eidelberg, D.
    MOVEMENT DISORDERS, 2007, 22 : S159 - S160
  • [16] Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease
    Ghilardi, M. F.
    Silvestri, G.
    Feigin, A.
    Mattis, P.
    Zgaljardic, D.
    Moisello, C.
    Crupi, D.
    Marinelli, L.
    DiRocco, A.
    Eidelberg, D.
    PARKINSONISM & RELATED DISORDERS, 2008, 14 (06) : 457 - 464
  • [17] Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data
    Christodoulou, Christiana C.
    Zachariou, Margarita
    Tomazou, Marios
    Karatzas, Evangelos
    Demetriou, Christiana A.
    Zamba-Papanicolaou, Eleni
    Spyrou, George M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 26
  • [18] Identification of psychoeducation needs and an intervention response for pre-symptomatic Huntington’s disease
    Cathy Gluyas
    Lisa Mottram
    Rosanne Gibb
    Julie Stout
    Journal of Community Genetics, 2023, 14 : 175 - 183
  • [19] Clinical assessment of mobility and balance impairments in pre-symptomatic Huntington's disease
    Rao, Ashwini K.
    Louis, Elan D.
    Marder, Karen S.
    GAIT & POSTURE, 2009, 30 (03) : 391 - 393
  • [20] Language deficits in pre-symptomatic Huntington's disease: Evidence from Hungarian
    Nemeth, Dezso
    Dye, Cristina D.
    Sefcsik, Tamas
    Janacsek, Karolina
    Turi, Zsolt
    Londe, Zsuzsa
    Klivenyi, Peter
    Kincses, Zsigmond Tamas
    Szabo, Nikoletta
    Vecsei, Laszlo
    Ullman, Michael T.
    BRAIN AND LANGUAGE, 2012, 121 (03) : 248 - 253